

## CURRICULUM VITAE

Name : **Vangelis (Evangelos) G. Manolopoulos**  
Address (work): Laboratory of Pharmacology, Medical School, Democritus University of Thrace,  
Dragana Campus, 68100 Alexandroupolis, Greece  
Tel / Fax: +30-25510-30523  
GSM: +30-69777-11119  
e-mail: [emanolop@med.duth.gr](mailto:emanolop@med.duth.gr)  
Place of birth: Athens, Greece  
DOB: 28 June 1961  
Citizenship: Greek  
Languages: Greek (mother tongue), English (fluent), French (very good), Dutch (good)  
Army service: Greek Air Forces, May to Dec 1997

### EDUCATION

1979-1984 University of Patras Applied Sciences School, Patras, Greece  
*Bachelor Degree in Biology*  
1987-1991 University of Patras Medical School, Patras, Greece  
*Doctorate (Ph.D) in Pharmacology*

### SCIENTIFIC POSITIONS

10/13 - **Professor**, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, and Clinical Pharmacology and Pharmacogenetics Unit, Academic General Hospital of Evros, Alexandroupolis, **Greece**  
01/09 – 10/13 **Associate Professor**, as above  
01/03 - 12/08 **Assistant Professor**, as above  
12/98 - 01/03 **Lecturer**, as above  
09/95 - 11/98 **Research Associate**, Laboratory of Physiology, Medical School, Katholieke Universiteit Leuven, **Belgium** (*Mentor: Prof Bernd Nilius*)  
07/97 - 12/97 **Researcher**, Department of Biomedical Research, 251 Air Forces General Hospital, Athens, **Greece**  
01/92 - 08/95 **Postdoctoral Fellow**, Laboratory of Cell Biology, Department of Medicine, University of Wisconsin Medical School, Milwaukee, WI, **USA**  
(*Mentor: Prof Peter I Lelkes*)  
01/87 - 12/91 **Research Assistant**, Department of Pharmacology, University of Patras Medical School, Patras, **Greece**  
10/89 - 07/90 **Visiting Scientist**, Department of Clinical Pharmacology, University of Groningen Medical School, Groningen, **The Netherlands**  
01/85 - 12/86 **Research Assistant**, Experimental Embryology Laboratory, University of Patras, **Greece**

### ADMINISTRATIVE POSITIONS

05/03 - 09/08: **Director**, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, **Greece**  
08/02 – 09/08: **Director**, Clinical Pharmacology and Pharmacogenetics Unit, Academic General Hospital of Evros, **Greece**

## MEMBERSHIP IN BOARDS OF SCIENTIFIC SOCIETIES

- European Society for Pharmacogenomics and Personalized Therapy (**ESPT**): Vice President (2014-2016), founding Board Member, Chair of Education and Courses Division (2011- ).
- Greek Society for Basic and Clinical Pharmacology (**GSP**): Vice President 2015-2017, constantly elected since 2003 on the Board in various positions (Treasurer 2003-2007, General Secretary 2007-2009 & 2013-2015)
- Greek Atherosclerosis Society: Member (2007-2009) and Head (2009-2011) of the Steering Board of the Working Group on the Study of Pathophysiology of Atherosclerosis.
- European Association of Clinical Pharmacology and Therapeutics (**EACPT**) Representative of Greek Pharmacological Society to the Board (2005-2007 and 2007-2011).

## MEMBERSHIP IN OTHER SCIENTIFIC SOCIETIES

- American Society for Pharmacology and Experimental Therapeutics (ASPET) since 1998
- European Association of Clinical Pharmacology and Therapeutics (EACPT ) individual member (2015)
- European Atherosclerosis Society (EAS) since 2011
- Atherosclerosis Society of Northern Greece (EABE) Founding member (2006)
- Greek Atherosclerosis Society (since 2003)

## MEMBERSHIP IN SCIENTIFIC COMMITTEES

- Ethics Board of Academic General Hospital of Evros: Member (2005-2009) και Head (2009-2015)
- Scientific Council of Academic Hospital of Evros (2005-2015)
- Drug Formulary Committee of Academic Hospital of Evros (2003-2011)
- Narcotics Committee of Academic Hospital of Evros (2003-2011)
- Internal Evaluation Committee of the Democritus University of Thrace Medical School (2008-2009)

## MEMBERSHIP IN CONSORTIA

- European Pharmacogenetics Implementation Consortium (**Eu-PIC**), Coordinator: Prof Ron van Schaik, Rotterdam, the Netherlands
- Pharmacogenetics in Childhood Asthma Consortium (**PICA**), Coordinator: Prof Anke-Hilse Maitland van der Zee, Utrecht, the Netherlands
- Clinical Pharmacogenetics Implementation Consortium (**CPIC**), USA-based guideline development platform of PharmGKB

## MEMBERSHIP IN JOURNAL EDITORIAL BOARDS

- Pharmacogenomics (since April 2011)
- Drug Metabolism & Personalised Therapy (formerly Drug Metabolism & Drug Interactions (since Nov 2010)
- Current Pharmacogenomics and Personalized Medicine (since Oct 2012)
- Hellenic Journal of Athrosclerosis (since Sep 2010)

## CHAIR OF ORGANIZING COMMITTEE OF MEETINGS

1. 2<sup>nd</sup> ESPT Summer School, “*Pharmacogenomics and other omics leading to personalized medicine: Established and emerging scientific, clinical and ethical aspects*”, Rome, Italy, 9-14 Jun, 2014
2. 1<sup>st</sup> ESPT Summer School, “*Basic Concepts in Pharmacogenomics and Theranostics*”, Ljubliana, Slovenia, 21-26 Aug, 2012.
3. ESPT Inaugural Symposium, Alexandroupolis, Greece, 8 Apr 2011.
4. 8<sup>th</sup> EACPT Summer School “*Clinical Pharmacology and Therapeutics*”, Alexandroupolis, Greece, 19-22 Sep, 2009.

## CLINICAL WORK

Throughout my 17-year presence at Democritus University of Thrace I have been offering my services to the Academic General Hospital of Evros to which the Medical school is affiliated. This activity is through the Clinical Pharmacology Unit which comprises of:

1. The **Therapeutic and Toxicological Drug Monitoring Branch**: It exists since 1992. I was its Head for 6 years (Aug 2002 to Sep 2008). This unit offers to physicians quick and reliable TDM service on a 24/7 basis. It caters to hospitals and other agencies (Forensics, Police, the military etc) in the entire geographic area of East Macedonia and Thrace. Approx. 12.000 analyses per year are performed, 60% of which involve prohibited substances and drugs of abuse and 40% therapeutic drug monitoring.
2. The **Pharmacogenetics Branch**: Since 2004 I have established and run a pharmacogenetics laboratory which aims at implementing pharmacogenomics in the clinic and training clinicians in its use and merits. So far we have established a regular pharmacogenetics service with the Psychiatry Department and receive yearly approx 100 patient samples for complete pharmacogenetic analysis in relation to psychiatric drugs. Occasionally we run samples also from Cardiology and other Departments. In addition, I have initiated several clinical research collaborations with various clinics with the aim of introducing them to Pharmacogenomics.

## CURRENT RESEARCH INTERESTS

- Clinical applications of pharmacogenomics in drugs for cardiovascular diseases, diabetes, anticoagulant therapy, childhood asthma, and psychiatric diseases.
- Personalized medicine in cardiovascular and psychiatric field (including epigenetics and other omics)
- Identification of novel genetic factors predisposing to atheromatosis, coronary artery disease, hypertension, diabetes, obesity, pediatric asthma, diabetic nephropathy, ischemic stroke.
- Hydrogen Sulfide (H<sub>2</sub>S): (patho)physiological actions, heterogeneity of regulation.
- Analysis of cardioprotective functions of natural compounds (pomegranate, asparagus officinalis)

## RECENT RESEARCH FUNDING

- Program THALIS / Greek Secretariat of Research and Technology: «*Hydrogen Sulfide (H<sub>2</sub>S) a new endogenous regulator of angiogenesis: signaling, physiology/ patho-physiology and development of pharmacological inhibitors*» (**H<sub>2</sub>S Biology**) / Total funding 521.000 € (80.000 € for my group) / co-investigator / 01/03/2012 – 30/09/2015.
- FP7-2007-HEALTH European Integrated Program,: «*European Pharmacogenomics of Anticoagulant Therapy*» (**EU-PACT**) in thematic line «Collaborative project HEALTH-2007-2.4.2-7: Integrating pharmacogenomic approaches into the treatment of cardiovascular disease» / European Consortium (12 Labs / 7 countries) / Total EU fundind: 3.000.000 € (295.000 € for Greece) / I was member of the Steering Board, and the National Coordinator and Principal Investigator for Greece / 01/10/2008 – 31/03/2013.
- Greek Atherosclerosis Society / Research Program: «*Study on the factors associated with vessel calcification in patients with diabetic nephropathy*» / 5.000 € / Principal Investigator of the program / 01/09/2011 – 31/08/2013.
- Greek Health Ministry, Special Account of Research & Development of 4<sup>th</sup> Health Periphery / Research Program: «*Genetic factors that govern the incidence of bronchial asthma in children and the therapeutic response of these patients to pharmacotherapy*» / 12.000 € / Principal Investigator / 01/01/2010 – 31/12/2010.
- Program TECHNOGENESIS / 2005-2006. Participated in Innovation Reinforcement Program “Technogenesis” of Region of Macedonia and Thrace with the proposal «*Center of Genomic-Pharmacogenomic Health Services*» that was evaluated in the 10 best proposals (among 300 submitted), received funding of 80.000 €, and was implemented with the foundation of a spin-off pharmacogenomic company.

**INVITED SPEAKER (last 5 years, selected from more than 50 in total)**

1. 2<sup>st</sup> European Spring School on Pulmonary Circulation and Right Ventricular Function, Chalkidiki, **Greece**, May 4-10, 2015, lecture title: “*Pharmacogenetic testing: does it have a place in thrombosis management?*”
2. 12<sup>th</sup> Congress of EACPT (European Congress of Clinical Pharmacology and Therapeutics), Madrid, **Spain**, Jun 27-30, 2015, 2 short lectures, titles: “*Pharmacogenetic profile of lipid response to atorvastatin in children with familial hypercholesterolemia*” & “*Effectiveness of acenocoumarol genetic and clinical dosing algorithms in predicting stable dose in the Greek cohort of the EU-PACT trial*”
3. 27<sup>th</sup> National Congress of Greek Neurologists, Alexandroupolis, **Greece**, Jun 6-9, 2015, lecture title: “*Clopidogrel, anticoagulants: pharmacogenomic correlations in clinical management*”
4. International Symposium on Advances in Predictive and Personalized Medicine, Istanbul, **Turkey**, Apr 2-3, 2015, lecture title: “*Pharmacogenomics and personalized medicine of antidiabetics*”
5. 4<sup>th</sup> International Conference of the Cyprus Society of Human Genetics (CSHG), Nicosia, **Cyprus**, Oct 10-12, 2014, lecture title “*Pharmacogenomics: a new tool for improvement of drug therapy*”
6. 7<sup>st</sup> Biologie Prospective Santorini Conference on Systems Medicine, Personalized Health, and Therapy, Santorini, **Greece**, Sep 25-27, 2014, lecture title: “*Pharmacogenomics of antidiabetic drugs*”
7. 2<sup>nd</sup> ESPT Summer School, Sapienza University, **Rome**, Italy, Jun 9-14, 2014, 2 lectures, titles: “*Clinical pharmacology: ADME systems*” and “*Cardiovascular Pharmacogenomics*”
8. 8<sup>th</sup> National Congress of the Greek Pharmacological Society, Athens, **Greece**, May 23-25, 2014, honorary lecture, title: “*Genotype-guided dosing of anticoagulants*”
9. San Andrea Hospital Symposium on Pharmacogenomics, Rome, **Italy**, Dec 16-17, 2013, lecture title: “*Coumarin anticoagulant personalized pharmacotherapy*”
10. 4<sup>th</sup> Pancyprian Psychiatry Congress, Larnaca, **Cyprus**, Sep 27-29, 2013, lecture title: “*Personalization of pharmacotherapy in psychiatry*”
11. ESPT 2<sup>nd</sup> Conference “Pharmacogenomics from cell to clinic”, Lisbon, **Portugal**, Sep 26-28, 2013, lecture title: “*Prospective clinical trials on coumarin anticoagulant pharmacogenomics: the moment of truth*”
12. 20<sup>th</sup> IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, Post-Congress Satellite Meeting on “Pharmacogenomics and Theranostics in practice”, Florence, **Italy**, May 24, 2013, lecture title: “*Pharmacogenomics of anticoagulants*”
13. 1<sup>st</sup> European Spring School on Pulmonary Circulation and Right Ventricular Function, Chalkidiki, **Greece**, May 6-12, 2013, lecture title: “*Pharmacogenetics of Vitamin K antagonists: ready for the clinical routine?*”
14. Marmara University Symposium on Personalized Medicine, Istanbul, **Turkey**, Apr 29, 2013, lecture title: “*Pharmacogenomics of anticoagulants*”
15. 1<sup>st</sup> International Meeting P4 Predictive, preventive, personalized, and Participatory Medicine, Anadolu University, Faculty of Pharmacy, Eskisehir, **Turkey**, Sep 13-16, 2012, lecture title: “*Pharmacogenetics of cardiovascular therapies: can this be applied in the clinic?*”
16. 1<sup>st</sup> ESPT Summer School, “Basic Concepts in Pharmacogenomics and Theranostics”, University of Ljubljana, Faculty of Pharmacy, Ljubljana, **Slovenia**, Aug 21-26, 2012, 2 lectures, titles: “*Clinical pharmacology: History, definitions, dimensions, role in drug development*” and “*Pharmacogenomics of drugs for the cardiovascular system*”
17. 1<sup>st</sup> International Conference on Familial hypercholesterolemia in children and adolescents, Athens, **Greece**, Jun 8-9, 2012, lecture title: “*Pharmacogenomics of statin effects in children and adults with familial hypercholesterolemia*”
18. 7<sup>th</sup> National Congress of the Greek Pharmacological Society, Thessaloniki, **Greece**, May 18-20, 2012, lecture title: “*Pharmacogenomics in anticoagulant and antiplatelet drug therapy: ready for clinical practice?*”
19. ArabMedLab 2012, 13<sup>th</sup> Arab Congress of Clinical Biology, Marrakesh, **Morocco**, May 2-5, 2012, lecture title: “*Pharmacogenetics of anticoagulants*”
20. Greek Society of Cardiology, National Congress, Thessaloniki, **Greece**, Feb 15-17, 2012, lecture title: “*Clinical relevance of genetic polymorphisms in coronary artery disease*”

21. International workshop on Clinical research, Extremadura University Hospital and Medical School, Badajoz, **Spain**, 28-29 Nov, 2011, lecture title: *“Pharmacogenetics of anticoagulants”*
22. 5<sup>th</sup> Crete Internal Medicine Congress, Herakleion, Crete, **Greece**, Oct 21-23, 2011, lecture title: *“Potential of pharmacogenomics to improve safety and effectiveness of drugs”*
23. 4<sup>th</sup> BBBB –Bled International Conference on Pharmaceutical Sciences “New Trends in Drug Discovery, Delivery Systems and Laboratory Diagnostics”, Bled, **Slovenia**, Sep 29-30, 2011, lecture title: *“Pharmacogenomics of anticoagulant and antiplatelet agents: ready for clinical practice?”*
24. 2<sup>nd</sup> Russian Scientific Conference with international participation, Medical and biological aspects of multifactorial disease, Kursk State Medical University, Kursk, **Russia**, May 18-20, 2011 lecture title: *“Pharmacogenomics of anticoagulant and antiplatelet agents in clinical cardiology practice”*

## OTHER SCIENTIFIC ACTIVITIES

- Participated in more than 20 electoral bodies for election and promotion of academic faculty members in the specialty of pharmacology and other specialties at the Medical School of DUTH.
- Participated in 15 electoral bodies for election and promotion of academic faculty members in the specialty of pharmacology and related fields at other Medical and Pharmacy Schools of Greece.
- Regularly participate in the University bodies (Sector General Assembly, Department General Assembly) and in various committees of Medical School of DUTH.
- Participated (with published abstracts) in more than 80 national and international scientific congresses
- Served as a member of organizing and/or Scientific Committee in more than 20 National and international scientific meetings and symposia.
- Reviewer of 15-20 research papers every year submitted for publication to reputed journals such as: Pharmacogenomics, Pharmacogenomics Journal, Pharmacogenetics and Genomics, Atherosclerosis, Human Genetics, Human Genomics, British Journal of Pharmacology, British Journal of Clinical Pharmacology, The Lancet, Molecular Psychiatry, Drug Metabolism and Drug Interactions, PLOS One, Personalized Medicine, Cell Calcium, Journal of Biochemistry and Molecular Biology etc.
- Reviewer of research proposals submitted for funding to Greek Secretariat of Research and Technology, to Ministry of Education of Romania (2011) and to Wellcome Trust Foundation (UK, 2012).
- Was twice an invited **Evaluator** of research proposals submitted to European Union in the thematic line of Framework Program 7 (FP7) (2007 and 2012) in research themes of cardiovascular system.
- Was an invited **Evaluator** and also **Review Panel Representative** in European Union HORIZON program (Brussels, Sep 15-20, 2014)
- Was an invited remote **Evaluator** of research proposals submitted to European Research Council COST program (Jun-Aug 2015)
- Represented the Greek Pharmacological Society at the European Pharmacological Societies (EPHAR) closed delegate meeting on developing the curriculum for the **European Certified Pharmacologist Diploma**, Utrecht, The Netherlands, Mar 27-28, 2014.
- Was an invited member of the scientific endorsement panel of the European Science Foundation (ESF) ‘Big Pictures’ workshop “Forward Look on Personalized Medicine for the European Citizen – towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM)”, Dubrovnik, Croatia 13-14 Feb, 2012
- Was an invited member of the endorsement panel of ESF Forward Look Stakeholder Conference on “Personalized Medicine for European Citizen”, 18 Apr 2012, Rome, Italy.
- Was invited to PHGEN II (Public Health Genomics II) Consortium Endorsement Panel and Final Conference, 19-20 April 2012, Rome, Italy.
- Participated in an official delegation of the **Research Directorate of the European Union** visiting **New Zealand** (Feb 24 to Mar 2, 2008) to discuss with local scientists and science officials issues of mutual collaboration. As part of this mission, we have visited the medical schools and other institutes of

biomedical sciences in Auckland, Dunedin, Christchurch and Wellington to promote the scientific relationships in Health Care research and education between Europe and New Zealand.

- Participated in more than 20 electoral bodies for election and promotion of academic faculty members in the specialty of pharmacology and other specialties at the Medical School of DUTH.
- Participated in 15 electoral bodies for election and promotion of academic faculty members in the specialty of pharmacology and related fields at other Medical and Pharmacy Schools of Greece.
- Regularly participate in the University bodies (Sector General Assembly, Department General Assembly) and in committees of Medical School of DUTH.
- Was awarded postgraduate and postdoctoral fellowships from the European Union (3 times), the Greek state, and the Belgian State.

## PUBLICATIONS

- **93 Publications in referenced international scientific journals**
- **Book Chapters in Books, e-papers: 6**
- **H-index : 27**
- **Total impact factor: 449.776**
- **Citations : approx 2320**

*[Individual Impact Factors and citations are shown in every citation. IF\* denotes journals that do not exist anymore, and the IF shown is the last available].*

## ORIGINAL RESEARCH PAPERS

1. Ragia G, Dahl ML, Manolopoulos VG “Influence of CYP3A5\*1 allele on the pharmacokinetics and clinical effects of psychiatric drug” *Current Drug Metabolism*, *accepted* (IF: 3.487)
2. Tavridou A, Georgoulidou A, Roumeliotis A, Roumeliotis S, Giannakopoulou E, Papanas N, Passadakis P, Manolopoulos VG, Vargemezis V, “Association of plasma adiponectin and oxidized low-density lipoprotein with carotid intima-media thickness in diabetic nephropathy” *Journal of Diabetes Research* 2015:507265, 2015. doi: 10.1155/2015/507265. (IF: 2.164, citations: 0)
3. Misailidis G, Ragia G, Ivanova DD, Tavridou A, Manolopoulos VG “Gene-gene interaction of  $\mu$ -opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect” *Drug Metabolism and Personalised Therapy* 30(2):129-35, 2015. (no IF, citations: 0)
4. Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH on behalf of the EU-PACT consortium “Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants” *Thrombosis Research* 136(1):69-75, 2015. (IF: 2.447, citations: 0)
5. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group (Barallon R, de Boer A, Daly A, Redekop K, Stingl J, Manolopoulos VG, Rosendaal FR, Wadelius M) “Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands” *Thrombosis Research* 136(1):94-100, 2015. (IF: 2.447, citations: 0)
6. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, van Schaik RHN, Kolovou G, Manolopoulos VG, “ No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4\*22) on lipid lowering response to statins in Greek patients with primary hypercholesterolemia” *Drug Metabolism and Personalised Therapy* 30(1):43-48, 2015. (no IF, citations: 6)
7. Kolovou G, Kolovou V, Ragia G, Mihas C, Diakoumakou O, Vasiliadis I, Mavrogeni S, Vartela V, Manolopoulos VG “CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin” *Genetics and Molecular Biology* 38(2):129-137, 2015. (IF 2014: 1.202, citations: 2)
8. Drogari E, Ragia G, Mollaki V, Elens L, Van Schaik RHN, Manolopoulos VG, “The P450 oxidoreductase \*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia” *Pharmacogenomics* 15(16):1963-1972, 2014. (IF:3.218, citation:1)

9. Ragia G, Giannakopoulou E, Karatza IM, Karaglani M, Tavridou A, Manolopoulos VG "Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance" *Drug Metabolism and Drug Interactions* 29(4):235-248, 2014. (no IF, citations: 4)
10. Iordanidou M, Paraskakis E, Giannakopoulou E, Tavridou A, Gentile G, Borro M, Simmaco M, Chatzimichail A, Bush A, Manolopoulos VG, "Vitamin D receptor *Apal* allele is associated with better childhood asthma control and improvement in ability for daily activities" *OMICS: A Journal of Integrative Biology* 18(11):673-681, 2014. (IF: 2.362, citations: 4)
11. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis A, Elisaf M, Kolovou G, Manolopoulos VG, "No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population" *Molecular Biology Reports* 41:4631-4638, 2014 (IF:2.024, citations:6)
12. Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans G, Lin D, van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kucinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O and Lønning PE, "Population Distribution and Ancestry of the Cancer Protective *MDM2* SNP285 (rs117039649)" *Oncotarget* 5(18):8223-8234, 2014. (IF: 6.359, citations: 1)
13. Kolovou G, Ragia G, Kolovou V, Mihas C, Katsiki N, Vasiliadis I, Mavrogeni S, Vartela V, Tavridou A, Manolopoulos VG "Impact of CYP3A5 gene polymorphism on efficacy of simvastatin" *The Open Cardiovascular Medicine Journal* 8:12-17, 2014. (no IF, citations: 5)
14. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis A, Elisaf M, van Schaik R, Kolovou G, Manolopoulos VG "Lack of association of the P450 oxidoreductase \*28 SNP with the lipid lowering response to statins in hypercholesterolemic patients" *Molecular Diagnosis & Therapy* 18(3): 323-331, 2014. (IF: 2.891, citations: 8)
15. Ragia G, Elens L, Tavridou A, van Schaik R, Manolopoulos VG "CYP2C9\*2 allele increases risk for hypoglycemia in POR\*1/\*1 type 2 diabetic patients treated with sulfonylureas" *Experimental and Clinical Endocrinology and Diabetes*, 122:60-63, 2014. (IF: 1.555, citations: 6)
16. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJM, Redekop WK, Remkes M, Rosendaal FR, van Schie RMF, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH, on behalf of EU-PACT group "A randomised controlled trial to assess the added value of *VKORC1* and *CYP2C9* genotyping before start of acenocoumarol and phenprocoumon treatment" *New England Journal of Medicine* 369:2304-2312, 2013. (IF:55.873, citations: 90)
17. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group (Barallon R, de Boer A, Daly A, Haschke-Becher E, Kamali F, Maitland-van der Zee AH, Redekop K, Stingl J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, Wadelius M). "A randomized trial of genotype-guided dosing of warfarin" *New England Journal of Medicine* 369(24):2294-2303, 2013. (IF: 55.873, citations: 95)
18. Alzahrani AM, Ragia G, Haneya H, Manolopoulos VG, "Genotyping of CYP2C9 and VKORC1 in the arabic population of Al-Ahsa, Saudi Arabia" *BioMed Research International*, vol. 2013, Article ID 315980, 2013. doi:10.1155/2013/315980. (IF: 1.579, citations: 4)
19. Ragia G, Iordanidou M, Giannakopoulou E, Tavridou A, Manolopoulos VG "Association of DRD2 Taq1A and DβH -1021C>T gene polymorphisms with smoking initiation and their interaction with serotonergic system gene polymorphisms" *Current Pharmacogenomics and Personalized Medicine* 11(2):110-117, 2013. (no IF, citations: 1)
20. Giannakopoulou E, Ragia G, Maroussi S, Elloul I, Manolopoulos VG, Tavridou A, "Association of monocyte chemoattractant protein-1 -2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke" *Neurological Sciences* 34(8):1315-1320, 2013. (IF: 1.447, citations: 3)
21. Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT Group (Barallon R, de Boer A, Daly A, Haschke-Becher E, Kamali

- F, Maitland-van der Zee AH, Redekop K, Stingl J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, Wadelius M) “Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation”. *Pharmacogenomics* 14(8):869-883, 2013. (IF: 3.218, citations: 7)
22. Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A “Association of functional *VKORC1* promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population” *Disease Markers* 35(6):641-646, 2013. (IF: 1.562, citations: 2)
  23. Staikos C, Ververidis A, Drosos G, Manolopoulos VG, Verettas D-A, Tavridou A “The association of adipokine levels in plasma and synovial fluid with the severity of knee osteoarthritis” *Rheumatology*, 52(6):1077-1083, 2013. (IF: 4.475, citations: 32)
  24. Ragia G, Tavridou A, Petridis I, Manolopoulos VG, “Association of *KCNJ11 E23K* gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients” *Diabetes Research and Clinical Practice* 98:119-124, 2012. (IF: 2.538, citations: 9)
  25. Verhoef TI, Redekop WK, Van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin L-A, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH, on behalf of the EU-PACT group. “Cost-effectiveness of pharmacogenetics in anticoagulation; international differences in healthcare systems and costs” *Pharmacogenomics* 13(12):1405-1417, 2012. (IF: 3.218, citations: 7)
  26. Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichail A, Manolopoulos VG, “G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting  $\beta_2$  agonists in asthmatic children” *Pharmacogenomics* 13(12):1363-1372, 2012. (IF: 3.218, citations: 8)
  27. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Barta C, Lu R-B, Zhukova OV, Kim J-J, Siniscalco M, New M, Li H, Kajuna S, Manolopoulos VG, Speed WC, Pakstis AJ, Kidd JR, Kidd KK “A global view of the OCA2-HERC2 region and pigmentation” *Human Genetics* 131(5):683-696, 2012. (IF: 4.824, citations: 32)
  28. Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH; EU-PACT group (Barallon R, de Boer A, Daly A, Haschke-Becher E, Kamali F, Maitland AH, Redekop K, Stingl J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, Wadelius M), “Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users” *Journal of Thrombosis Haemostasis* 10(12):2610-2612, 2012. (IF: 5.720, citations: 15)
  29. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; EU-PACT Group. “Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users” *Journal of Thrombosis Haemostasis* 10(4):606-14, 2012. (IF: 5.720, citations: 15)
  30. van Schie RM, Babajeff AM, Schalekamp T, Wessels JA, le Cessie S, de Boer A, van der Meer FJ, van Meegen E, Verhoef TI, Rosendaal FR, Maitland-van der Zee AH; EU-PACT study group. “An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol” *Journal of Thrombosis Haemostasis* 10(5):767-72, 2012. (IF: 5.720, citations: 6)
  31. Stathias V, Sotiris GR, Karagiannidis I, Bourikas G, Martinis G, Papazoglou D, Tavridou A, Papanas N, Maltezos E, Theodoridis M, Vargemezis V, Manolopoulos VG, Speed WC, Kidd JR, Kidd KK, Drineas P, Paschou P “Exploring genomic structure differences and similarities between the Greek and European HapMap populations; implications for association studies” *Annals of Human Genetics* 76(6):472-483, 2012. (IF: 2.211, citations: 5)
  32. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F; EU-PACT Study Group (de Boer A, Daly AK, Haschke-Becher E, Maitland-van der Zee AH, Manolopoulos VG, Redekop WK, Rosendaal FR, Stingl J). A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. *Clinical Pharmacology and Therapeutics* 90(5):701-706, 2011. (IF: 7.903, citations: 46)
  33. Tavridou A, Petridis I, Vasiliadis M, Ragia G, Heliopoulos I, Vargemezis V, Manolopoulos VG “Association of VKORC1 -1639 G>A polymorphism with intima-media thickness in type 2 diabetes

- mellitus” *Diabetes Research and Clinical Practice* 94:236-241, 2011. (IF: 2.538, citations: 7)
34. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, de Boer A, Daly AK, Haschke-Becher E, Kamali F, Manolopoulos VG, Pirmohamed M, Redekop WK, Rosendaal FR, Stingl J, Wadelius M, Maitland-van der Zee AH. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *European Heart Journal* 32(15):1909-17, 2011. (IF: 15.203, citations: 59)
  35. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms -786T>C and 894G>T in coronary artery bypass graft surgery patients” *Human Genomics* 4(6):1-9, 2010. (no IF, citations: 13)
  36. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. “Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia” *Heart & Vessels* 25(4):288-293, 2010. (IF: 2.065, citations: 19)
  37. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee A-H, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RMF, Wadelius M. “A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives” *Pharmacogenomics* 11(7): 989-1002, 2010. (IF: 3.218, citations: 17)
  38. Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG “The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes” *Clinica Chimica Acta* 411:167-171, 2010. (IF: 2.824, citations: 33)
  39. Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, Manolopoulos VG “Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians”, *Drug and Alcohol Dependence* 108:70-76, 2010. (IF: 3.423, citations: 18)
  40. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Mehdi SO, Kajuna SLB, Barta C, Kungulilo S, Karoma NJ, Lu R-B, Zhukova OV, Kim J-J, Comas D, Siniscalco M, New M, Li P, Li H, Manolopoulos VG, Speed WC, Rajeevan H, Pakstis AJ, Kidd JR, Kidd KK. “The Distribution and Most Recent Common Ancestor of the 17q21 Inversion in Humans”,. *American Journal of Human Genetics* 86(2):161-171, 2010. (IF: 10.931, citations: 28)
  41. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis G, Bougioukas G, Manolopoulos VG “Renin-angiotensin system gene polymorphisms in coronary artery bypass graft surgery patients” *Journal of Renin Angiotensin Aldosterone System* 11(2):136-145, 2010 (IF:2.400, citations:9)
  42. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG, " Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19\*17 discovery: The case of Greece" *Pharmacogenomics* 10: 43-49, 2009. (IF: 3.218, citations: 47)
  43. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H “Oxidized low-density lipoprotein and arterial function in beta-thalassemia major” *European Journal of Haematology* 82: 477-483, 2009. (IF: 2.066, citations: 11)
  44. Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis J, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG " Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population” *Diabetes Research and Clinical Practice* 84(2): 132-137, 2009. (IF: 2.538, citations: 11)
  45. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG, “Presence of CYP2C9\*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulphonylurea oral hypoglycemic agents” *Pharmacogenomics* 10: 1781-1787, 2009. (IF: 3.218, citations: 42)
  46. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekkas E, Kourounakis PN, Charalambos A, Manolopoulos VG, "Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit" *Journal of Cardiovascular Pharmacology* 51(6):573-580, 2008. (IF: 2.111, citations: 9)
  47. Iordanidou M, Tavridou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis DA, Vargemezis V, Bougioukas G, Manolopoulos VG, “The -759 C/T polymorphism of the 5-HT<sub>2C</sub> receptor is associated

- with type II diabetes in male and female Caucasians” *Pharmacogenetics & Genomics*, 18 (2):153-159, 2008. (IF: 3.481, citations: 11)
48. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. “Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population”. *Fundamental and Clinical Pharmacology*, 21 (4): 419-426, 2007. (IF: 2.121, citations: 71)
  49. Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG, "EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate eNOS expression in cultured endothelial cells" *Endothelium*, 14 (4): 239-243, 2007. (IF\*: 1.929, citations: 16)
  50. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG, “EP2306, a novel squalene synthase inhibitor, inhibits atherosclerosis in the cholesterol-fed rabbit”. *Journal of Pharmacology Experimental Therapeutics*, 323(3): 794-804, 2007. (IF: 3.972, citations: 15)
  51. Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka E, Kourounakis PN, Charalambous A, Manolopoulos VG, "Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and atherosclerosis". *European Journal of Pharmacology*, 535: 34-42, 2006. (IF: 2.532, citations: 39)
  52. Tentes AAK, Markakidis SK, Karanikiotis C, Fiska A, Tentes AK, Manolopoulos VG, Dimitriou T, “Intra-arterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer”. *Langenbeck’s Archives of Surgery*, 391: 124-129, 2006. (IF: 2.191, citations: 4)
  53. Tavridou A, Manolopoulos VG, "Atorvastatin and simvastatin decrease the uptake of acetylated-low density lipoprotein by human monocytes”, *Pharmacology* 73: 102-105, 2005. (IF: 1.672, citations: 3)
  54. Tavridou A, Manolopoulos VG, "Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo” *European Journal of Pharmacology* 505: 213-221, 2004. (IF: 2.532, citations: 23)
  55. Papadimitriou E, Waters CR, Manolopoulos VG, Unsworth BR, Maragoudakis ME, Lelkes PI, “Regulation of extracellular matrix remodeling and MMP-2 activation in cultured rat adrenal medullary endothelial cells”, *Endothelium* 8: 181-194, 2001. (IF\*: 1.929, citations: 11)
  56. Manolopoulos VG, Liekens S, Koolwijk P, Voets T, Peters E, Droogmans G, Lelkes PI, De Clercq E, Nilius B, “Inhibition of angiogenesis by blockers of volume-regulated anion channels”, *General Pharmacology* 34: 107-116, 2000. (IF\*: 1.986, citations: 44)
  57. Suh SH, Vennekens R, Manolopoulos VG, Freichel M, Schweig U, Prenen J, Flockerzi V, Droogmans G, Nilius B, “Characterization of explanted endothelial cells from mouse aorta: electrophysiology and Ca<sup>2+</sup>-signalling”, *Pflügers Archiv European Journal of Physiology* 438:612-20, 1999 (IF:4.101, citations: 67)
  58. Mountian I, Manolopoulos VG, De Smedt H, Parys JB, Missiaen L, Wuytack F, “Expression patterns of sarco/endoplasmic reticulum Ca<sup>2+</sup>-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells”, *Cell Calcium* 25: 371-380, 1999. (IF: 3.513, citations: 58)
  59. Voets T, Manolopoulos V, Eggermont J, Ellory C, Droogmans G, Nilius B, “Regulation of swelling-activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins”, *Journal of Physiology (London)* 506: 341-352, 1998. (IF: 5.139, citations: 145)
  60. Manolopoulos VG, Fenton II JW, Lelkes PI, "The thrombin receptor in adrenal medullary endothelial cells is negatively coupled to adenylyl cyclase through a G<sub>i</sub>-protein" *Biochimica Biophysica Acta* 1356: 321-332, 1997. (IF: 4.381, citations: 23)
  61. Papadimitriou E, Manolopoulos VG, Hayman GT, Maragoudakis ME, Unsworth BR, Fenton JW, Lelkes PI, “Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells”, *American Journal of Physiology (Cell Physiology)* 272: C1112-C1122, 1997. (IF: 3.780, citations: 48)
  62. Manolopoulos VG, Voets T, Declercq PE, Droogmans G, Nilius B, “Swelling-activated efflux of taurine and other organic osmolytes in endothelial cells”, *American Journal of Physiology (Cell Physiology)* 273: C214-C222, 1997. (IF: 3.780, citations: 42)
  63. Manolopoulos VG, Droogmans G, Nilius B, “Hypotonicity and thrombin activate taurine efflux in BC3H1

- and C2C12 myoblasts that is down regulated during differentiation”, *Biochemical Biophysical Research Communications* 232: 74-79, 1997. (IF: 2.297, citations: 26)
64. Manolopoulos VG, Prenen J, Droogmans G, Nilius B, “Thrombin potentiates volume-activated chloride currents in pulmonary artery endothelial cells” *Pflügers Archiv European Journal of Physiology* 433: 845-847, 1997. (IF: 4.101, citations: 19)
  65. Silverman MD, Manolopoulos VG, Unsworth BR, Lelkes PI, "Tissue factor expression is differentially modulated by cyclic mechanical strain in various human endothelial cells", *Blood, Coagulation, and Fibrinolysis* 7: 281-288, 1996. (IF: 1.403, citations: 24)
  66. Efthimiopoulos S, Punj S, Manolopoulos V, Pangalos M, Wang GP, Refolo LM, Robakis NK, "Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein", *Journal of Neurochemistry* 67: 872-875, 1996. (IF: 4.281, citations: 55)
  67. Manolopoulos VG, Samet MM, Lelkes PI, "Regulation of the adenylyl cyclase signaling system in various types of cultured endothelial cells", *Journal of Cellular Biochemistry* 57:590-598, 1995. (IF: 3.263, citations: 34)
  68. Manolopoulos VG, Liu J, Unsworth BR, Lelkes PI, "Adenylyl cyclase isoforms are differentially expressed in primary cultures of endothelial cells and whole tissue homogenates from various rat tissues", *Biochemical Biophysical Research Communications* 208: 323-331, 1995 (IF 2014: 2.297, citations: 45)
  69. Manolopoulos VG, Lelkes PI, "Cyclic strain and forskolin differentially induce cAMP production in phenotypically diverse endothelial cells", *Biochemical Biophysical Research Communications* 191: 1379-85, 1993. (IF: 2.297, citations: 34)
  70. Manolopoulos VG, Pipili-Synetos E, den Hertog A, Nelemans A, "Inositol phosphates formed in rat aorta after  $\alpha_1$ -adrenergic stimulation are inhibited by forskolin", *European Journal of Pharmacology* 207: 29-36, 1991. (IF: 2.532, citations: 26)
  71. Synetos D, Manolopoulos VG, Atlas D, Pipili-Synetos E, "A human plasma-derived material with clonidine displacing substance (CDS)-like properties, contracts the isolated rat aorta", *Journal of Autonomic Pharmacology* 11: 343-351, 1991. (I.F\*: 1.825, citations: 22)
  72. Pipili E, Manolopoulos VG, Catravas JD, Maragoudakis ME, "Angiotensin converting enzyme activity is present in the endothelium-denuded aorta", *British Journal of Pharmacology* 98: 333-335, 1989. (IF: 4.842, citations: 40)

## REVIEW ARTICLES, LETTERS & COMMENTS

1. Ragia G, Dahl ML Manolopoulos VG “CYP3A5 genetic polymorphism: is it important for psychiatric drugs?” *Current Drug Metabolism*, submitted
2. Belley-Cote EP, Hanif H, D’Aragon F, Eikelboom JW, Anderson JL, Borgman M, Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee AH, Pirmohamed M, Whitlock RP “Genotype-Guided Versus Standard Vitamin K Antagonist Dosing Algorithms in Patients Initiating Anticoagulation: A Systematic Review and Meta-Analysis” *Thrombosis Haemostasis* 114(3): 2015. (IF: 4.984, citations: 0)
3. Ragia G, Manolopoulos VG “Pharmacogenomics of Alcohol Addiction: Personalizing Pharmacologic Treatment of Alcohol Dependence” *Hospital Pharmacology* 1(3):147-167, 2014. (no IF, citations: 1)
4. Hekim N, 28 authors, Manolopoulos VG, 12 authors, Özdemir V, “Translating Biotechnology to Knowledge-based Innovation, Peace and Development? Deploy a Science Peace Corps -- An Open Letter to World Leaders” *OMICS: A Journal of Integrative Biology* 18(7):415-420, 2014. (IF: 2.362, citations: 2)
5. Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group. “Genotype-guided dosing of vitamin K antagonists”. *New England Journal of Medicine* 370(18):1765-1766, 2014. (IF: 55.873, citations: 1)
6. Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulos VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M on behalf of the EU-PACT study group “Patients benefit from genetics-guided warfarin therapy” *Clinical Pharmacology and Therapeutics* 96:15-17, 2014. (IF: 7.903, citations: 0)

7. Özdemir V, Borda-Rodriguez A, Dove ES, Ferguson LR, Huzair F, Manolopoulos VG, Masellis M, Milius D, Warnich L, Srivastava S, “Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation” *Current Pharmacogenomics and Personalized Medicine* 11(1):1-4, 2013. (no IF, citations: 5)
8. Ragia G, Manolopoulos VG “Research highlights” *Pharmacogenomics* 13(3):261-264, 2012. (IF:3.218, citations: 0)
9. Manolopoulos VG, Ragia G, Alevizopoulos G, “Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics” *Drug Metabolism and Drug Interactions* 27(1):19-31, 2012. (no IF, citations: 6)
10. Manolopoulos VG, Ragia G, Tavridou A “Pharmacogenomics of oral antidiabetic treatment: current data and pharmacoepigenomic perspective” *Pharmacogenomics* 12(8):1161-1191,2011 (IF:3.218,citations:31)
11. Manolopoulos VG, Dechairo B, Huriez A, Kuehn A, Llerena A, Van Schaik R, Yeo J, Ragia G, Siest G, “Fifth Santorini conference pharmacogenomics roundtable report: Pharmacogenomics and personalized medicine in clinical practice” *Pharmacogenomics* 12(5):681-691, 2011. (IF: 3.218, citations: 10)
12. Tavridou A, Ragia G, Manolopoulos VG “Emerging targets for the treatment of dyslipidemia” *Current Medicinal Chemistry* 18(6):909-922, 2011. (IF: 3.853, citations: 17)
13. Squassina A, Artac M, Manolopoulos VG, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Manchia M, Del Zompo M, Patrinos GP. “Translation of genetic knowledge into clinical practice: the expectations and realities of pharmacogenomics and personalized medicine” *Pharmacogenomics* 11(8):1149-1167, 2010. (IF: 3.218, citations: 3)
14. Manolopoulos VG, Ragia G, Tavridou A “Pharmacogenetics of Coumarinic Oral Anticoagulants” *Pharmacogenomics* 11(4): 493-496, 2010. (IF: 3.218, citations: 44)
15. Tavridou A, Manolopoulos VG, “EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors” *Current Pharmaceutical Design* 15(27): 3167-3178, 2009. (IF: 3.452, citations: 9)
16. Manolopoulos VG, Tavridou A, “Drugs targeting atherosclerosis: current and emerging approaches” *Current Pharmaceutical Design* 15(27):3091-3093, 2009. (IF: 3.452, citations: 1)
17. Tavridou A, Manolopoulos VG, “Inhibitors of 5-lipoxygenase activating protein (FLAP) – WO20080-30369” *Expert Opinion on Therapeutic Patents*, 19(10): 1473-1476, 2009. (IF: 4.297, citations: 1)
18. van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland-van der Zee A-H, “Genotype-guided dosing of coumarin derivatives: the European pharmacogenomics of anticoagulant therapy (EU-PACT) trial design” *Pharmacogenomics* 10: 1287-1295, 2009. (IF: 3.218, citations: 95)
19. Tavridou A, Manolopoulos VG, “Novel molecules targeting dyslipidemia and atherosclerosis” *Current Medicinal Chemistry* 15 (8): 792-802, 2008. (IF: 3.853, citations: 24)
20. A Llerena, G Michel, E Jeannesson, S Wong, VG Manolopoulos, et al. “Third Santorini conference pharmacogenomics workshop report: Pharmacogenomics at the crossroads: What else than good science will be needed for the field to become part of personalized medicine?”. *Clinical Chemistry and Laboratory Medicine*, 45: 843-850, 2007. (IF: 2.707, citations: 5)
21. VG Manolopoulos. “Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice”. *Clinical Chemistry and Laboratory Medicine*, 45: 801-814, 2007. (I.F. 2014: 2.707, citations: 27)
22. D Gurwitz, Lunshof J, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, J Licinio, A Llerena, VG Manolopoulos, LJ Sheffield, G Siest, F Torricelli, V Vasiliou, S Wong. “Pharmacogenomics education: International society of pharmacogenomics recommendations for medical, pharmaceutical and health schools deans of education” *Pharmacogenomics Journal*, 5: 221-225, 2005. (IF: 4.229, citations: 81)
23. B Nilius, J Eggermont, T Voets, G Buyse, V Manolopoulos, G Droogmans, “Properties of volume-regulated anion channels in mammalian cells”, *Progress in Biophysics and Molecular Biology* 68: 69-119, 1997. (IF: 2.274, citations: 286)

## CHAPTERS IN BOOKS / e-PUBLICATIONS

1. Manolopoulos VG, Ragia G, "Pharmacogenomics of oral antidiabetic drugs" in *Handbook of Pharmacogenomics and Stratified Medicine* (edited by S Padmanabhan) Elsevier, Amsterdam, p. 683-713, 2014.
2. Manolopoulos VG, "Pharmacogenomics of anticoagulant and antiplatelet agents in clinical cardiology practice" *Kursk Medical Journal* vol 2, p. 153-159, 2011.
3. Gurwitz D, Manolopoulos VG, "Personalized Medicine" in *Comprehensive Medicinal Chemistry II* (eds D. Triggle, J Taylor), Volume 1: Global Perspective (Volume editor P.D. Kennewell) Elsevier, Amsterdam, p. 279-295, 2007.
4. Tavridou A, Manolopoulos VG, "CoA reductase inhibitors (Statins)" published in July 2006 at the official site of the **International Atherosclerosis Society** ([www.athero.org/commentaries/comm550.asp](http://www.athero.org/commentaries/comm550.asp)).
5. Lelkes PI, Manolopoulos VG, Silverman M, Zhang S, Carmiol S, Unsworth BR, "On the possible role of endothelial cell heterogeneity in angiogenesis" In: *Molecular, cellular, and clinical aspects of angiogenesis* (ed. Maragoudakis ME), Plenum Press, New York, p.1-17, 1996.
6. Lelkes PI, Manolopoulos VG, Chick D, Unsworth BR, "Endothelial cell heterogeneity and organ-specificity" In: *Angiogenesis: Molecular Biology, Clinical Aspects* (ed. Maragoudakis ME), Plenum Press, New York, p. 15-28, 1994.

## TEACHING RECORD

### A. UNDERGRADUATE

- **Pharmacology** (lectures and laboratory exercises) for Medical students (2 semesters, continuously since 1999). Between 2002 and 2008 I have been the Course director.
- Course director of 1-semester elective course in **Pharmacogenetics** for medical students. I have developed this course from scratch and started offering it in the 2001-02 academic year. It was the first pharmacogenetics course in the country (at either under- or postgraduate level) and one of the first in Europe. It is regularly selected attended by approx 40-50% of the students eligible for it. I have also developed a dedicated syllabus and other teaching material for the course.
- Course director of 1-semester elective course in **Pharmacology** for students of School of Molecular Biology and Genetics in Alexandroupolis (2002-2006).
- Supervisor in 1-2 Diploma research projects every year of students of School of Molecular Biology and Genetics in Alexandroupolis. Until now, 10 such Theses have been completed.
- Supervisor of bibliographic and research projects of medical students presented in National Congresses of Medical students.
- Participated in laboratory and research training of undergraduate medical students at the dutch-speaking Leuven University in Belgium (1995-1998).
- Participated in laboratory and research training of undergraduate students of medicine and pharmacy at University of Patras (1987-1991).

### B. POSTGRADUATE

- Associate Scientific Director (1<sup>st</sup> cycle) and Lecturer at the Master's Degree Program **Clinical Pharmacology and Therapeutics** initiated in Sep 2006 in Alexandroupolis and organized by my department at the Medical School of DUTH. Course Director: Prof. G. Kolios. The program runs in 3 semesters (2 course work, 1 semester research thesis) and it is popular among pharmacy graduates.
- Member of Coordinating Committee and Lecturer in Master's Degree Program **Social Psychiatry** initiated in Sep 2008 and organized by the Psychiatry Department of DUTH. Course Director: Assoc. Prof M. Samakouri.
- Teach regularly a course in pharmacological principles as part of the professional training of nurses of

my hospital.

- Supervisor in PhD thesis completed and defended in Dec 2009 by **Ms Georgia Ragia**, Molecular Biologist, (currently Senior scientific officer in the Greek Pharmacogenetics company) titled “*Study of clinically important genetic polymorphisms of the human genome associated with cardiovascular disease*”.
- Supervisor in PhD thesis completed and defended in Nov 2013 by **Dr Maria Iordanidou**, MD (currently Pediatrics resident), titled “*Genetic factors that govern the incidence of bronchial asthma in children and the response of these patients to pharmacotherapy*”.
- Supervisor or co-supervisor in 3 active PhD theses
- Supervisor in 3 completed Master’s Degree Thesis of students of postgraduate Master’s Program “**Clinical Pharmacology and Therapeutics**”:
  - **Maria Petridou**, Agricultural engineer, “*Epidemiologic investigation of pesticides use of agriculturists of region of Drama*”, 2008.
  - **Apostolos Sapountzis**, MD, Internist, “*Association study of Vitamin K epoxide reductase subunit 1-Vkorc1 gene polymorphism with arterial hypertension in a population of Western Thrace*”, 2009.
  - **Efstathia Giannakopoulou**, Molecular Biologist, “*Impact of SLCO1B1 gene polymorphisms encoding organic anion transporter OATP1B1 on the hypolipidemic effect of statins*”, 2013.
- External evaluator in PhD Thesis of **Mr Marc Rancier** titled “*Study of the genomics of VEGF in relation to clinical endocrinology*”, Department of Pharmacy, University of Lorraine, Nancy, **France** (awarded Mar 2015)
- External evaluator in PhD Thesis of **Mr Payhaman Shahabi** titled “*Cytochrome P450 and Inflammation; Pharmacogenetic Approach and Molecular Aspects of Anti-inflammatory Effects of Thienopyridines*” Department of Pharmacy, University of Lorraine, Nancy, **France** (awarded Sep 2013)
- Remote external evaluator in PhD Thesis of **Mr Nirupama Devi** titled “*Renin angiotensin aldosterone system gene polymorphisms in acute coronary syndrome*” Department of Human Genetics, Andhara University, Visakhapatnam, Andhara Pradesh, **India** (awarded Nov 2013)
- Participated in laboratory and research training of postgraduate medical students at the Catholic Flemish University of Leuven (1995-1998).
- Participated in laboratory and research training of postgraduate students at Cell Biology Laboratory at Medical School of Wisconsin University (1992-1995) and in laboratory training of resident physicians at Mount Sinai Hospital, Milwaukee, WI (1992-1995).